Advanced in Essential Thrombocythemia

Dr. Anna B. Halpern

Hematology Oncology | Hematology | Oncology
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Advanced in Essential Thrombocythemia
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anna Halpern is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Halpern is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration. Dr. Halpern is currently accepting new patients.

Her clinical research consists of co-authoring 54 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Essential Thrombocythemia.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
University Of Washington Medical Ctr
Languages Spoken
English
Hindi
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Procedure, Drug
Study Drugs: Daunorubicin, Cytarabine
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Enrollment Status: Terminated
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: MBG453, Hypomethylating agents
Study Phase: Phase 2
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study
Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Other, Biological, Drug
Study Drugs: Cladribine, Cytarabine, Filgrastim, Mitoxantrone, Sorafenib
Study Phase: Phase 1/Phase 2
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: June 02, 2022
Intervention Type: Procedure, Drug
Study Drug: Decitabine
Study Phase: Phase 2
Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study
Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study
Enrollment Status: Completed
Publish Date: March 08, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor, Mitoxantrone
Study Phase: Phase 2
Integrating a Telemonitoring Device Into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study
Integrating a Telemonitoring Device Into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study
Enrollment Status: Terminated
Publish Date: January 10, 2020
Intervention Type: Other, Device, Procedure
Study Phase: Not Applicable
View 6 Less Clinical Trials

54 Total Publications

Pre-Hematopoietic Cell Transplant Ruxolitinib in Transplant-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.
Pre-Hematopoietic Cell Transplant Ruxolitinib in Transplant-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.
Journal: Transplantation and cellular therapy
Published: July 21, 2025
Similar Doctors
David M. Aboulafia
Distinguished in Essential Thrombocythemia
Dr. David M. Aboulafia
Hematology Oncology | Hematology | Oncology
Distinguished in Essential Thrombocythemia
Dr. David M. Aboulafia
Hematology Oncology | Hematology | Oncology

Virginia Mason Medical Center

925 Seneca St, 
Seattle, WA 
 (1.1 miles away)
206-223-6600
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Aboulafia is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Aboulafia is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Non-Hodgkin Lymphoma, Anal Cancer, Kaposi Sarcoma, B-Cell Lymphoma, and Splenectomy. Dr. Aboulafia is currently accepting new patients.

Distinguished in Essential Thrombocythemia
Dr. Min-chun C. Chen
Hematology Oncology | Hematology | Oncology
Distinguished in Essential Thrombocythemia
Dr. Min-chun C. Chen
Hematology Oncology | Hematology | Oncology
1003 S 5th St, Ste 3l, 
Tacoma, WA 
 (26.1 miles away)
253-403-1677
Languages Spoken:
English, Castilian, Danish, Hakka, Hindi, Japanese, Mandarin, Portuguese, Punjabi, Russian, Spanish, Taiwanese, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Min-chun Chen is a Hematologist Oncology specialist and a Hematologist in Tacoma, Washington. Dr. Chen is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Essential Thrombocythemia, Myeloproliferative Neoplasms (MPN), Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Myelogenous Leukemia (CML). Dr. Chen is currently accepting new patients.

Distinguished in Essential Thrombocythemia
Dr. Ndegwa M. Njuguna
Hematology Oncology | Hematology | Oncology
Distinguished in Essential Thrombocythemia
Dr. Ndegwa M. Njuguna
Hematology Oncology | Hematology | Oncology

Northwest Medical Specialties PLLC

34509 9th Ave S, Suite 107, 
Federal Way, WA 
 (23.1 miles away)
253-428-8700
Languages Spoken:
English, Bengali, German, Konkani, Sinhala, Spanish, Swahili
See accepted insurances
Accepting New Patients
Offers Telehealth

Ndegwa Njuguna is a Hematologist Oncology specialist and a Hematologist in Federal Way, Washington. Dr. Njuguna is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Dehydration, Chronic B-Cell Leukemia (CBCL), Pleuropulmonary Blastoma, and Acute Mountain Sickness. Dr. Njuguna is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Halpern's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile